Literature DB >> 10335795

Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors.

R K Lister, M Youle, D R Nair, A F Winder, M H Rustin.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10335795     DOI： 10.1016/s0140-6736(99)01449-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Madhu N Rao; Grace A Lee; Carl Grunfeld
Journal:  Am J Infect Dis       Date:  2006-09-30

Review 2.  The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

Authors:  Grace A Lee; Madhu N Rao; Carl Grunfeld
Journal:  Curr HIV/AIDS Rep       Date:  2005-02       Impact factor: 5.071

3.  Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype.

Authors:  M Shahmanesh; H Jaleel; Y DeSilva; J D Ross; M Caslake; R Cramb
Journal:  Sex Transm Infect       Date:  2001-08       Impact factor: 3.519

4.  Metabolic effects of indinavir in healthy HIV-seronegative men.

Authors:  M A Noor; J C Lo; K Mulligan; J M Schwarz; R A Halvorsen; M Schambelan; C Grunfeld
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

5.  The Effects of HIV Protease Inhibitors on Carbohydrate and Lipid Metabolism.

Authors:  Grace A Lee; Madhu N Rao; Carl Grunfeld
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.